Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Background: Chronic spontaneous urticaria (CSU) is a common condition treated by allergist/immunologists, but the only FDA-approved biologic medication, omalizumab, may be underutilized globally. Objective: This study was performed to determine the global prescription of omalizumab for treatment of...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Christine J. Rubeiz, MD, Ricardo Asero, MD, Stephen Betschel, HBSc, MD, FRCP (C), Timothy Craig, DO, Anete Grumach, MD, PhD, Michihiro Hide, MD, PhD, David Lang, MD, Michael Levin, MD, PhD, Hilary Longhurst, MA, PhD, FRACP, FRCPath, Eli Magan, MD, Marcus Maurer, MD, Romi Saini, MD, Gordon Sussman, MD, Elias Toubi, MD, Dinh Nguyen Van, MD, PhD, Torsten Zuberier, MD, Jonathan A. Bernstein, MD
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2024-01-01
Saila:	World Allergy Organization Journal
Gaiak:	Chronic spontaneous urticaria Clinical research Safety Adverse effects Monitoring Biologics
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S1939455123001187
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!